Dealmaking 1996: The Year in Review
While the drug industry continued to shun acquisitions in favor of alliances, service and device companies see mergers as the only way to go. Can diagnostics, still stubbornly unconsolidated, be far behind?
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.